Health care costs of breast,prostate, colorectal and lung cancer care by clinical stage and cost component |
| |
Institution: | 1. Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Gipuzkoa, Spain;2. Biodonostia Health Research Institute, Donostia-San Sebastián, Spain;3. RS-Statistics, Arrasate-Mondragón, Gipuzkoa, Spain;4. Basque Health Service (Osakidetza), Donostia University Hospital, Pharmacy Services, Donostia-San Sebastián, Spain;5. Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Accounting Department, Arrasate-Mondragón, Gipuzkoa, Spain;6. Kronikgune Institute for Health Service Research, Barakaldo, Bizkaia, Spain;7. Mondragon Unibertsitatea, Faculty of Engineering, Arrasate-Mondragón, Gipuzkoa, Spain;8. Basque Health Service (Osakidetza), Donostia University Hospital, Medical Oncology Service, Donostia-San Sebastián, Spain |
| |
Abstract: | ObjectiveTo measure 3-year care costs of breast, prostate, colorectal and lung cancers disaggregated by site and clinical stage.MethodA retrospective observational design was employed to investigate care costs of cases recorded in the Registry of the Basque Country between 2010 and 2015. Data gathered included TNM stage and demographic, clinical and resource use variables. Total costs per patient with stage IV disease were calculated by combining generalized linear models with parametric survival analysis. Unit costs were obtained from the analytical accounting system of the Basque Health Service.ResultsThe sample comprised 23,782 cancer cases (7801 colorectal, 5530 breast, 4802 prostate and 5649 lung cancer). The mean 3-year costs per patient with stage I to III disease were €11,323, €13,727, €8,651 and €12,023 for colorectal, breast, prostate and lung cancer, respectively. The most important cost components were surgery and chemotherapy. Total survival-adjusted costs until death for patients with stage IV disease (€27,568, €26,296, €16,151 and €15,931 for breast, colorectal, lung and prostate cancer, respectively) were higher than the 3-year costs for those with earlier-stage disease.ConclusionsThis study quantitatively shows the pattern of changes in the economic burden of cancer throughout its natural history and the great magnitude of this burden for the health system. The use of indicators based on real-world data from each regional health service would allow cancer care in each region to be tailored to local population needs. |
| |
Keywords: | Colorectal cancer Breast cancer Lung cancer Prostate cancer TNM stage Costs Chemotherapy Radiotherapy Surgery Real-world data Cáncer colorrectal Cáncer de mama Cáncer de pulmón Cáncer de próstata Estadio TNM Costes Quimioterapia Radioterapia Cirugía Datos del mundo real |
本文献已被 ScienceDirect 等数据库收录! |
|